<DOC>
	<DOCNO>NCT00546377</DOCNO>
	<brief_summary>RATIONALE : Pentostatin may stop growth cancer cell block enzymes need cell growth . Drugs use chemotherapy , cyclophosphamide mitoxantrone , work different way stop growth cancer cell , either kill cell stop dividing . Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Giving pentostatin together combination chemotherapy rituximab may kill cancer cell . PURPOSE : This phase I/II trial study side effect best dose mitoxantrone give together pentostatin , cyclophosphamide , rituximab see well work treat patient chronic lymphocytic leukemia low-grade B-cell cancer .</brief_summary>
	<brief_title>Pentostatin , Cyclophosphamide , Rituximab , Mitoxantrone Treating Patients With Chronic Lymphocytic Leukemia Other Low-Grade B-Cell Cancer</brief_title>
	<detailed_description>OUTLINE : This phase I , dose-escalation study mitoxantrone hydrochloride follow phase II study . - Phase I : Patients receive pentostatin IV , cyclophosphamide IV , mitoxantrone hydrochloride IV day 1 . Patients also receive rituximab IV day 1 begin course 2 . Treatment repeat every 4 week 6 course absence disease progression unacceptable toxicity . - Phase II : Patients receive pentostatin , cyclophosphamide , rituximab , mitoxantrone hydrochloride ( maximum tolerate dose determine phase I ) phase I . All patient receive either pegfilgrastim subcutaneously ( SC ) day 1-4 follow course filgrastim sargramostim SC begin 2 day course blood count recover . Patients undergo blood collection bone marrow biopsy periodically assessment therapy response biomarker laboratory study . Samples analyze molecular genetics IgH arrangement PCR response immunoelectrophoresis . Some sample analyze response flow cytometry fluorescence situ hybridization ( FISH ) . After completion study treatment , patient follow every 3 month 1 year . PROJECTED ACCRUAL : A total 63 patient ( 18 patient phase I 45 patient phase II ) accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>Pentostatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis 1 follow disease confirm Memorial SloanKettering Cancer Center ( MSKCC ) pathologist : Chronic lymphocytic leukemia meeting follow risk criterion define threestage Rai system : Intermediaterisk disease meeting follow criterion active disease define NCI Working Group : Weight loss Fatigue Fevers Evidence progressive marrow failure Splenomegaly Progressive lymphadenopathy Progressive lymphocytosis rapid doubling time , define double time le 6 month absolute lymphocyte count &gt; 30,000/μL Highrisk disease Other low grade Bcell neoplasms , include follow : Small lymphocytic lymphoma Follicular lymphoma Waldenstrom macroglobulinemia Marginal zone lymphoma Mantle cell lymphoma Transformed lymphoma Previously treat disease Must receive prior cytotoxic therapy Malignant lymphocytes must demonstrate Bcells via immunophenotypic immunohistochemical analysis NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Karnofsky performance status 60100 % Life expectancy &gt; 8 week Total bilirubin ≤ 2.0 mg/dL ( patient Gilbert disease autoimmune hemolytic anemia evaluation cause hyperbilirubinemia , none find , may enrol regardless serum bilirubin ) Total creatinine ≤ 2.0 mg/dL OR creatinine clearance &gt; 50 mL/min Not pregnant nursing Fertile patient must use effective contraception Normal cardiac ejection fraction ≥ 50 % ( increased ejection fraction [ least 5 % rest ] ) require study eligibility Borderline ( 4050 % ) ejection fraction must undergo stress echocardiogram MUGA scan Patients autoimmune hemolytic anemia autoimmune thrombocytopenia eligible treatment Must undergone consultation primary investigator his/her designee prior study entry No significant active infection No ongoing hepatitis B infection , specifically hepatitis B antigen surface antigen positivity Hepatitis B antibodypositive patient eligible PRIOR CONCURRENT THERAPY : See Disease Characteristics The following concurrent medication allow : Intravenous immunoglobulin ( IVIG ) Erythropoietin , darbepoetin , filgrastim , sargramostim Cyclosporine ( patient cellular immune cytopenia [ i.e. , pure red cell aplasia ] ) , require consultation principle investigator designee Concurrent prednisone allow provide used brief course ( ≤ 7 day ) inflammatory condition unrelated CLL No concurrent chemotherapy radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
</DOC>